Tellimer

IN : Indoco Remedies Ltd - Expect strong earnings ahead

4QFY21 revenue and PAT were in line; the exports business continued its growth momentum while the India business underperformed. India business revenues declined in 4Q due to degrowth in its key therapies, but management expects a strong recovery in FY22. We reiterate our rating to Add with higher TP of Rs410 at 20x FY23F P/E.


Most Viewed See latest
Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not con...

Full Tellimer disclaimers